Cell Therapy Manufacturing Market by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts (5th Edition), 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    553

  • View Count
    29766

Example Insights

Cell-Therapy-Manufacturing-Market-Context-thumb Cell-Therapy-Manufacturing-Market-Landscape-thumb Cell-Therapy-Manufacturing-Market-Distribution-by-Type-of-Manufacturer-thumb Cell-Therapy-Manufacturing-Market-Prominent-Industry-Headquarters-thumb Cell-Therapy-Manufacturing-Market-Partnerships-and-Collaborations-thumb
Cell-Therapy-Manufacturing-Market-Mergers-and-Acquisitions-thumb Cell-Therapy-Manufacturing-Market-Recent-Expansions-thumb Cell-Therapy-Manufacturing-Market-Total-Cost-of-Ownership-thumb Cell-Therapy-Manufacturing-Market-Big-Pharma-Initiatives-thumb Cell-Therapy-Manufacturing-Market-List-of-Automated-Cell-thumb
Cell-Therapy-Manufacturing-Market-Capacity-Analysis-thumb Cell-Therapy-Manufacturing-Market-Demand-Analysis-thumb Cell-Therapy-Manufacturing-Market-Current-Market-thumb Cell-Therapy-Manufacturing-Market-Growth-thumb  

Overview

The cost of cell-based therapies depends on various factors, such as duration of manufacturing, vector-based cell transfection and extent of gene modification. Price of such products has been observed to vary between USD 2,000 (for cartilage implants) to USD 50,000-60,000 (for cell and gene therapies).

-- CEO, a small-sized cell therapies manufacturer

Driven by numerous developmental breakthroughs and results of studies demonstrating the vast potential of cellular therapies in the treatment of rare disorders, this therapeutic modality has garnered considerable attention of players engaged in the healthcare industry, in the past few years. In this context, it is worth noting that, since 2019, over 1,035 clinical studies focused on such cell therapy candidates have been initiated. Moreover, several commercialized cell therapies have emerged as top selling drugs in the healthcare industry. For instance, Kymriah® has registered sales worth over USD 1.5 billion since its launch in 2018. Considering the sufficient body of evidence validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process. Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products (such as cell therapy manufacturing), thereby, making such products more affordable. One such emerging concept, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. However, the delicate nature of steps involved in the cell therapy manufacturing process is known to hinder the overall automation process. Further, the lack of specialized infrastructure and limited expertise available in this domain are some of the known challenges impacting the growth of this segment. 

At present, the market landscape for cell therapy manufacturing is fragmented, featuring a mix of in-house manufacturers and contract service providers. Further, in order to ensure the optimum use of their resources and enable additional revenue generation opportunities, a number of innovator companies engaged in this market also offer contract services, in addition to their in-house manufacturing capabilities. Considering the growing demand for cell therapies, players engaged in this industry are undertaking several initiatives to ensure that they are able to cater to the requirements of their clients. Since 2020, a considerable increase in both partnership and expansion activity has been observed within the overall cell therapy domain. It is also worth highlighting that the increasing interest and involvement of big pharma players in this market has been instrumental in escalation of the adoption of such therapies. In recent years, several big pharma players have undertaken initiatives, including establishing strategic partnerships with other industry players and carrying out expansion projects, in order to enhance their cell therapy manufacturing capabilities. Considering the ongoing efforts of stakeholders to mitigate the manufacturing associated complications and an enhanced emphasis on the advancement of such therapies, the cell therapy manufacturing market is anticipated to witness significant growth in the foreseen future.

Scope of the Report

The “Cell Therapy Manufacturing Market by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts (5th Edition), 2022-2035” report features an extensive study of the current market landscape and future opportunities associated with the cell therapy manufacturing market, along with information on both contract manufacturers, as well as developers having in-house manufacturing capabilities, offering an in-depth analyses of the various business entities engaged in this domain, across key geographic locations. Amongst other elements, the report includes:

  • A general overview of cell therapies, along with information on the key challenges and factors influencing the cell therapy manufacturing market. It provides details on the automation tools and technologies being utilized for improving manufacturing processes and the future prospects in this domain.
  • A detailed review of the overall market landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cells manufactured (including immune cells (T cells, dendritic cells, NK cells), stem cells (adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), location of headquarters and their respective manufacturing facilities. 
  • A discussion on cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
  • An overview of the various roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing processes.
  • An elaborate discussion on the role of technology automation in order to improve the current manufacturing methods, along with a comparative (qualitive) analysis of the cost differences between manual and automated processes.
  • Elaborate profiles of key industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales of operation. Each profile features a brief overview of the company, along with details related to its cell therapy manufacturing service portfolio, its manufacturing capabilities and facilities, recent partnerships and an informed future outlook. 
  • Elaborate profiles of non-industry players that offer contract manufacturing services for cell therapies, featuring an overview of the organization, along with details related to its cell therapy manufacturing service portfolio and manufacturing facilities.
  • A discussion on the role of non-profit organizations, featuring a list of organizations that are actively involved in the development and production of cell-based therapies, across different geographical locations, along with information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.
  • An analysis of completed, ongoing and planned clinical trials, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active industry and non-industry players (in terms of number of clinical trials conducted) and regional distribution of trials.
  • A detailed analysis of the recent partnerships and collaborations inked by players focused on the manufacturing of cell-based therapies, during the period 2016-2022, based on several relevant parameters, such as the year of agreement, type of partnership model adopted, type of cells manufactured and scale of operation.
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2016-2022, based on several relevant parameters, such as year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
  • An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
  • An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
  • Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions. 
  • A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • An in-depth analysis of cell therapy manufacturers using three versatile representations, namely, a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cell manufactured, scale of operation and purpose of production, a logo landscape, based on the type of cell manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific), and type and size of organization (non-industry players, and small, mid-sized and large companies), and a schematic world map representation, highlighting the geographical location of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
  • A collection of key insights derived from the study, including a grid analysis, two logo landscapes and two schematic world map representations highlighting various offerings and details of the cell therapy manufacturing service providers across different continents. 
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
  • Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on relevant parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such therapies, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long-term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] type of cell therapy (T cell therapies, dendritic cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Peter Coleman (Chief Executive Officer, RoslinCT)
  • Dominic Clarke (Chief Technical Officer, Cell and Gene Therapy, Discovery Life Sciences)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Gilles Devillers (General Manager, Bio Elpida)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Arik Hasson (Executive VP Research and Development, Kadimastem)
  • Fiona Bellot (Ex-Business Development Manager, Roslin CT)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
  • Victor Lietao Li (Ex- Co-Founder and Chief Executive Officer, Lion TCR) 
  • Arnaud Deladeriere (Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy) 
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Ex-Department Leader, Cell Therapy Innovation and Development, Yposkesi)
  • Tim Oldham (Ex-Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
  • What is the current, installed contract manufacturing capacity for cell therapies?
  • What are the key parameters governing the price of cell therapies?
  • What are the key recent developments (such as partnerships and expansions) that have been undertaken in the field of cell therapies? 
  • What kind of partnership models are commonly adopted by stakeholders engaged in the cell therapy manufacturing domain? 
  • What are the different types of initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
  • What are the different types of automated technology platforms that are available to be adopted for the development and manufacturing of cell therapies? 
  • Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
  • What is the estimated total capital expenditure required to set up a cell therapy manufacturing facility?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies? 
  • How is the current and future market opportunity likely to be distributed across various key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cell-based Therapies
3.2.1. Comparison of Cell-based Therapies and Other Biotechnological Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape of ATMPs

3.3. Overview of Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing
3.4.2. Decentralized Manufacturing
3.5. Scalability of Cell Therapy Manufacturing Processes
3.5.1. Scale-up
3.5.2. Scale-out

3.6. Types of Cell Therapy Manufacturers
3.7. Key Challenges for Manufacturing Cell Therapies
3.8. Key Factors Influencing Cell Therapy Manufacturing
3.8.1. Characterization
3.8.2. Cost of Goods
3.9. Automation of Cell Therapy Manufacturing Processes
3.10. Cell Therapy Manufacturing Supply Chain
3.11. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturing (Industry Players): Overall Market Landscape
4.2.1. Analysis by Company Size
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Year of Establishment and Location of Headquarters
4.2.6. Analysis by Location of Manufacturing Facility
4.2.7. Analysis by Type of Manufacturer
4.2.8. Analysis by Location of Headquarters and Type of Manufacturer

4.2.9. Analysis by Type of Cell Manufactured
4.2.10. Analysis by Company Size and Type of Cell Manufactured
4.2.11. Analysis by Location of Headquarters and Type of Cell Manufactured
4.2.12. Analysis by Source of Cells
4.2.13. Analysis by Type of Cell Manufactured and Source of Cells
4.2.14. Analysis by Scale of Operation
4.2.15. Analysis by Manufacturing Capabilities / Services Offered
4.2.16. Analysis by Company Size and Services Offered
4.2.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered

4.3. Cell Therapy Manufacturing (Non-Industry Players): Overall Market Landscape
4.3.1. Analysis by Organization Size
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Organization Size and Location of Headquarters
4.3.5. Analysis by Year of Establishment and Location of Headquarters
4.3.6. Analysis by Location of Manufacturing Facility
4.3.7. Analysis by Type of Manufacturer
4.3.8. Analysis by Location of Headquarters and Type of Manufacturer

4.3.9. Analysis by Type of Cell Manufactured
4.3.10. Analysis by Organization Size and Type of Cell Manufactured
4.3.11. Analysis by Location of Headquarters and Type of Cell Manufactured
4.3.12. Analysis by Source of Cells
4.3.13. Analysis by Type of Cell Manufactured and Source of Cells
4.3.14. Analysis by Scale of Operation
4.3.15. Analysis by Manufacturing Capabilities / Services Offered
4.3.16. Analysis by Organization Size and Services Offered
4.3.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered

5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory Guidelines in North America
5.2.2. Regulatory Guidelines in Europe
5.2.3. Regulatory Guidelines in Japan
5.2.4. Regulatory Guidelines in China
5.2.5. Conditional Approvals

5.3. Regulatory Accreditations for Cell Therapy Manufacturing
5.3.1. Facilities Approved by Regulators to Manufacture Cell Therapies
5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies
5.5. Existing Challenges to Clinical-Stage Manufacturing of Cell Therapies
5.5.1. Variability in Regulatory Guidelines across Different Geographies

6. ROADMAPS FOR OVERCOMING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Logistics
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Manufacturing Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Growth Drivers and Roadblocks
7.4. Case Studies
7.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
7.4.2. Automating the Cell Therapy Manufacturing Process
7.5. GMP-in-a-Box
7.6. List of Automated and Closed Cell Therapy Processing Systems
7.7. Comparative Analysis of Manual and Automated Processes

8. PROFILES: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Service Providers in North America
8.2.1 AGC Biologics
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Facilities and Capabilities
8.2.1.4. Recent Developments and Future Outlook

8.2.2. Charles River Laboratories
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Facilities and Capabilities
8.2.2.4. Recent Developments and Future Outlook

8.2.3. KBI Biopharma
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Facilities and Capabilities
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Thermo Fisher Scientific
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Manufacturing Facilities and Capabilities
8.2.4.4. Recent Developments and Future Outlook

8.3. Service Providers in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Facilities and Capabilities
8.3.1.4. Recent Developments and Future Outlook

8.3.2. Cell and Gene Therapy Catapult
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Manufacturing Facilities and Capabilities
8.3.2.4. Recent Developments and Future Outlook

8.3.3. Lonza
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Facilities and Capabilities
8.3.3.4. Recent Developments and Future Outlook

8.3.4. RoslinCT
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.3. Manufacturing Facilities and Capabilities
8.3.4.4. Recent Developments and Future Outlook

8.4. Service Providers in Asia Pacific
8.4.1. Cell Therapies
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Manufacturing Facilities and Capabilities
8.4.1.4. Recent Developments and Future Outlook

8.4.2. FUJIFILM Cellular Dynamics
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Manufacturing Facilities and Capabilities
8.4.2.4. Recent Developments and Future Outlook

8.4.3. Minaris Regenerative Medicine
8.4.3.1. Company Overview
8.4.3.2. Service Portfolio
8.4.3.3. Manufacturing Facilities and Capabilities
8.4.3.4. Recent Developments and Future Outlook

8.4.4. MEDINET
8.4.4.1. Company Overview
8.4.4.2. Service Portfolio
8.4.4.3. Manufacturing Facilities and Capabilities
8.4.4.4. Recent Developments and Future Outlook

8.4.5. Nikon CeLL Innovation
8.4.5.1. Company Overview
8.4.5.2. Service Portfolio
8.4.5.3. Manufacturing Facilities and Capabilities
8.4.5.4. Recent Developments and Future Outlook

8.4.6. WuXi AppTec
8.4.6.1. Company Overview
8.4.6.2. Service Portfolio
8.4.6.3. Manufacturing Facilities and Capabilities
8.4.6.4. Recent Developments and Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities

9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.3.1. Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities

9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.4.1. Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities

9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
9.5.1. Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities

9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.6.1. Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities

9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.7.1. Overview
9.7.2. Service Portfolio
9.7.3. Manufacturing Facilities and Capabilities

9.8. Newcastle Cellular Therapies Facility, Newcastle University
9.8.1. Overview
9.8.2. Service Portfolio
9.8.3. Manufacturing Facilities and Capabilities

9.9. Rayne Cell Therapy Suite, King’s College London
9.9.1. Overview
9.9.2. Manufacturing Facilities and Capabilities

9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
9.10.1. Overview
9.10.2. Manufacturing Facilities and Capabilities

9.11. Sydney Cell and Gene Therapy
9.11.1. Overview
9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center
10.2.3. National Cell Manufacturing Consortium (NCMC)
10.2.4. California Institute of Regenerative Medicine (CIRM)
10.3. Cell Therapy Manufacturing: International Societies

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cell Therapies: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Registration Year and Trial Status
11.4.5. Analysis by Trial Phase
11.4.6. Analysis of Enrolled Patient Population Trial Phase
11.4.7. Analysis by Type of Sponsor / Collaborator
11.4.8. Analysis by Patient Segment
11.4.9. Analysis by Study Design
11.4.10. Most Active Players: Analysis by Number of Registered Trials
11.4.11. Analysis by Number of Trials and Geography
11.4.12. Analysis by Number of Trials, Trial Status and Geography
11.4.13. Analysis by Enrolled Patient Population, Trial Status and Geography

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models

12.3. Cell Therapy Manufacturing: List of Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership

12.4. Analysis by Type of Cell Manufactured

12.5. Analysis by Scale of Operation

12.6. Analysis by Region
12.6.1. Continent-wise Distribution
12.6.2. Country-wise Distribution

12.7. Most Active Players: Analysis by Number of Partnerships

12.8. Cell Therapy Manufacturing: List of Mergers and Acquisitions
12.8.1. Analysis by Year of Agreement
12.8.2. Analysis by Type of Agreement
12.8.3. Analysis by Year of Acquisition and Type of Cell Manufactured
12.8.4. Analysis by Region
12.8.4.1. Continent-wise Distribution
12.8.4.2. Country-wise Distribution
12.8.4.3. Intercontinental and Intracontinental Deals
12.8.5. Ownership Change Matrix

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Cell Therapy Manufacturing: List of Expansions
13.2.1. Cumulative Year-wise Distribution
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Types of Cells Manufactured
13.2.4. Analysis by Scale of Operation
13.2.5. Analysis by Location of Manufacturing Facility
13.2.6. Analysis by Type of Expansion and Location of Manufacturing Facility
13.2.7. Most Active Players: Analysis by Number of Expansions
13.2.8. Most Active Players: Analysis by Area of Expansion
13.2.9. Analysis by Year and Location of Manufacturing Facility

14. BIG PHARMA INITIATIVES
14.1. Chapter Overview
14.2. Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Type of Initiative
14.2.3.1. Analysis by Type of Partnership
14.2.3.2. Analysis by Type of Expansion

14.2.4. Analysis by Types of Cells Manufactured
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis of Big Pharma Players by Year of Initiative
14.2.7. Analysis by Year and Type of Initiative
14.2.8. Analysis of Big Pharma Players by Types of Cells Manufactured
14.2.9. Analysis of Big Pharma Players by Scale of Operation

14.3. Competitive Benchmarking of Big Pharmaceutical Players
14.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
14.3.2. Spider Web Analysis: Big Pharmaceutical Players

15. CAPACITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology (Industry Players)
15.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
15.2.1.1. Analysis by Company Size
15.2.1.2. Analysis by Scale of Operation
15.2.1.3. Analysis by Location of Manufacturing Facility
15.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
15.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility

15.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
15.2.2.1. Analysis by Company Size
15.2.2.2. Analysis by Scale of Operation
15.2.2.3. Analysis by Location of Manufacturing Facility
15.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
15.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility

15.3. Key Assumptions and Methodology (Non-Industry Players)
15.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
15.3.1.1. Analysis by Scale of Operation
15.3.1.2. Analysis by Location of Manufacturing Facility
15.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
15.3.2.1. Analysis by Scale of Operation
15.3.2.2. Analysis by Location of Manufacturing Facility
15.4 Concluding Remarks

16. DEMAND ANALYSIS
16.1 Chapter Overview
16.2 Scope and Methodology
16.3 Global Demand for Cell Therapy Manufacturing
16.4 Global Clinical Demand for Cell Therapy Manufacturing
16.4.1. Analysis by Type of Cell Therapy
16.4.2. Analysis by Geography
16.5. Global Commercial Demand for Cell Therapy Manufacturing
16.5.1. Analysis by Type of Cell Therapy
16.5.2. Analysis by Geography

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell Therapies
17.3. Pricing Models for Cell Therapies
17.3.1. Based on Associated Costs for T-Cell Therapies
17.3.2. Based on Associated Costs for Stem Cell Therapies
17.3.3. Based on Availability of Competing Products
17.3.4. Based on Target Patient Segment
17.3.5. Based on the Opinions of Industry Experts
17.4. Cell Therapy Cost Optimization
17.4.1. Role of Cost of Goods Sold
17.4.2. Role of Automation
17.5. Role of Cell Therapy Contract Manufacturing Organizations
17.6. Reimbursement-related Considerations for Cell Therapies
17.6.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

18. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
18.3.1. Scenario 1
18.3.2. Scenario 2
18.3.3. Scenario 3
18.3.4. Scenario 4
18.4. Concluding Remarks

19. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS
19.1. Chapter Overview
19.2. Key Parameters
19.3. Assumptions and Methodology
19.4. Sample Dataset for the Estimation of Total Cost of Ownership
19.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
19.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
19.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
19.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

20. MARKET SIZING AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope of the Forecast
20.3. Input Data and Key Assumptions
20.4. Forecast Methodology
20.5. Global Cell Therapy Manufacturing Market, 2022-2035
20.5.1. Cell Therapy Manufacturing Market: Analysis by Type of Cell Therapy, 2022-2035
20.5.2. Cell Therapy Manufacturing Market: Analysis by Source of Cells, 2022-2035
20.5.3. Cell Therapy Manufacturing Market: Analysis by Scale of Operation, 2022-2035
20.5.4. Cell Therapy Manufacturing Market: Analysis by Purpose of Manufacturing, 2022-2035 
20.5.5. Cell Therapy Manufacturing Market: Analysis by Region, 2022-2035

20.6. Cell Therapy Manufacturing Market for Commercial Scale Manufacturing
20.6.1. Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035
20.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
20.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region

20.6.2. Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035
20.6.2.1. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.2.2. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region

20.6.3. Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
20.6.3.1. Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035: Analysis by Region
20.6.4. Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
20.6.4.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.4.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region

20.7. Cell Therapy Manufacturing Market for Clinical Scale Manufacturing
20.7.1. Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035
20.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
20.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region

20.7.2. Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
20.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Region

20.7.3. Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035
20.7.3.1. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.3.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region

20.7.4. Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
20.7.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region

21. KEY INSIGHTS
21.1. Chapter Overview
21.2. Cell Therapy Manufacturing: Grid Analysis
21.3. Cell Therapy Manufacturing: Logo Landscape
21.3.1. Immune Cell Therapy Manufacturing: Logo Landscape
21.3.2. Stem Cell Therapy Manufacturing: Logo Landscape
21.4. Cell Therapy Manufacturing: World Map Representation based on Location of Manufacturing Facilities
21.4.1. Industry Players
21.4.2. Non-Industry Players

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors

23. CONCLUDING REMARKS
23.1. Chapter Overview

24. SURVEY ANALYSIS
24.1. Chapter Overview
24.2. Analysis by Designation of Respondents
24.3. Analysis by Type of Cell Therapy
24.4. Analysis by Scale of Operation
24.5. Analysis by Source of Cells
24.6. Analysis by Type of Cell Culture System Used
24.7. Analysis by Availability of Fill / Finish Services

25. INTERVIEW TRANSCRIPTS
25.1. Chapter Overview
25.2. RoslinCT
25.2.1. Company Overview
25.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer

25.3. Discovery Life Sciences
25.3.1. Company Overview
25.3.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell and Gene Therapy

25.4. Glycostem Therapeutics
25.4.1. Company Overview
25.4.2. Interview Transcript: Troels Jordansen, Chief Executive Officer

25.5. Bio Elpida
25.5.1. Company Overview
25.5.2. Interview Transcript: Gilles Devillers, President

25.6. Gracell Biotechnologies
25.6.1. Company Overview
25.6.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer

25.7. Kadimastem
25.7.1. Company Overview
25.7.2. Interview Transcript: Arik Hasson, Executive VP Research and Development

25.8. RoslinCT
25.8.1. Company Overview
25.8.2. Interview Transcript: Fiona Bellot, Ex-Business Development Manager

25.9. University of Minnesota
25.9.1. Company Overview
25.9.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine

25.10. Lion TCR
25.10.1. Company Overview
25.10.2. Interview Transcript: Victor Lietao Li, Ex- Co-Founder and Chief Executive Officer

25.11. Center for Commercialization of Cancer Immunotherapy / C3i
25.11.1. Company Overview
25.11.2. Interview Transcript: Arnaud Deladeriere, Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit

25.12. Waisman Biomanufacturing
25.12.1. Company Overview
25.12.2. Interview Transcript: Brian Dattilo, Manager of Business Development

25.13. Yposkesi
25.13.1. Company Overview
25.13.2. Interview Transcript: Mathilde Girard, Ex-Department Leader, Cell Therapy Innovation and Development

25.14. Cell Therapies
25.14.1. Company Overview
25.14.2. Interview Transcript: Tim Oldham, Ex-Chief Executive Officer

25.15. CiMaas
25.15.1. Company Overview
25.15.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer 

26. APPENDIX 1: TABULATED DATA27. APPENDIX

27: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Mergers and Acquisitions
Figure 2.5 Executive Summary: Recent Expansions
Figure 2.6 Executive Summary: Big Pharma Initiatives
Figure 2.7 Executive Summary: Capacity Analysis
Figure 2.8 Executive Summary: Demand Analysis
Figure 2.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 3.2 Decentralized Manufacturing: Process Model
Figure 3.3 Cell Therapy Manufacturing: Type of Manufacturers
Figure 3.4 Cell Therapies: Key Challenges and Drivers
Figure 3.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 3.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 4.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Figure 4.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Figure 4.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 4.6 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment and Location of Headquarters
Figure 4.7 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 4.8 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Figure 4.10 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Figure 4.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 4.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.14 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Type of Cell Manufactured
Figure 4.15 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 4.16 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Figure 4.17 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured and Source of Cells
Figure 4.18 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Figure 4.19 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 4.20 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Services Offered
Figure 4.21 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Figure 4.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size
Figure 4.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment
Figure 4.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.25 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Figure 4.27 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment and Location of Headquarters
Figure 4.28 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.29 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.30 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Figure 4.31 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Figure 4.32 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
Figure 4.33 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.34 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.35 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Type of Cell Manufactured
Figure 4.36 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 4.37 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Figure 4.38 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured and Source of Cells
Figure 4.39 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Figure 4.40 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 4.41 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Services Offered
Figure 4.42 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Figure 5.1 Cell Therapy Manufacturing (Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities / Certifications
Figure 5.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities / Certifications
Figure 7.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 7.2 Pre-Requisites for Implementing Closed Systems in Cell Therapy Manufacturing Processes
Figure 7.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 7.4 Advantages and Disadvantages Associated with Single-Use Systems
Figure 7.5 Growth Drivers and Roadblocks Related to the Adoption of Automated and Closed Systems
Figure 7.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 7.7 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes
Figure 7.8 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Affiliated Costs
Figure 8.1 AGC Biologics: Service Portfolio
Figure 8.2 Charles River Laboratories: Service Portfolio
Figure 8.3 KBI Biopharma: Service Portfolio
Figure 8.4 Thermo Fisher Scientific: Service Portfolio
Figure 8.5 BioNTech Innovative Manufacturing Services: Service Portfolio
Figure 8.6 Cell and Gene Therapy Catapult: Services
Figure 8.7 Lonza: Business Divisions
Figure 8.8 Lonza: Historical Timeline
Figure 8.9 Lonza: Service Portfolio
Figure 8.10 Lonza: Biological Manufacturing Services
Figure 8.11 Lonza: Cell-based Products
Figure 8.12 RoslinCT: Service Portfolio
Figure 8.13 Cell Therapies: Service Portfolio
Figure 8.14 FUJIFILM Cellular Dynamics: Service Portfolio
Figure 8.15 Minaris Regenerative Medicine: Service Portfolio
Figure 8.16 MEDINET: Service Portfolio
Figure 8.17 Nikon CeLL Innovation: Service Portfolio
Figure 8.18 WuXi AppTec: Service Portfolio
Figure 9.1 Center for Cell and Gene Therapy: Operating Segments
Figure 9.2 Center for Cell and Gene Therapy: Service Portfolio
Figure 9.3 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 9.4 Clinical Cell and Vaccine Production Facility: Service Portfolio
Figure 9.5 Guy’s and St Thomas’ GMP Facility: Service Portfolio
Figure 9.6 Laboratory for Cell and Gene Medicine: Service Portfolio
Figure 9.7 Molecular and Cellular Therapeutics: Service Portfolio
Figure 9.8 Newcastle Cellular Therapies Facility: Service Portfolio
Figure 9.9 Rayne Cell Therapy Suite, King’s College London: Service Portfolio
Figure 9.10 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Center for Regenerative Medicine: Service Portfolio
Figure 9.11 Sydney Cell and Gene Therapy: Service Portfolio
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2022
Figure 11.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2022
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution of Number of Trials by Enrolled Patient Population and Trial Phase
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 11.10 Clinical Trial Analysis: Distribution by Study Design
Figure 11.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.13 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 11.14 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Figure 11.15 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Cells
Figure 12.5 Heat Map: Distribution by Year and Type of Cells
Figure 12.6 Partnerships and Collaborations: Distribution by Type of T-Cells
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 12.8 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 12.9 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Figure 12.10 Partnerships and Collaborations: Country-wise Distribution
Figure 12.11 Partnerships and Collaborations: Continent-wise Distribution
Figure 12.12 Most Active Players: Distribution by Number of Partnerships
Figure 12.13 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022
Figure 12.14 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 12.15 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Figure 12.16 Mergers and Acquisitions: Country-wise Distribution
Figure 12.17 Mergers and Acquisitions: Continent-wise Distribution
Figure 12.18 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 12.19 Mergers and Acquisitions: Ownership Change Matrix
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 13.4 Recent Expansions: Distribution by Type of Cells Manufactured
Figure 13.5 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Figure 13.6 Recent Expansions: Distribution by Scale of Operation
Figure 13.7 Recent Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 13.8 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 13.9 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Figure 13.10 Most Active Players: Distribution by Number of Expansions
Figure 13.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
Figure 13.12 Recent Expansions: Distribution by Year and Location of Manufacturing Facility
Figure 14.1 Big Pharma Initiatives: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Figure 14.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2017-2022
Figure 14.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 14.4 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 14.5 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 14.6 Big Pharma Initiatives: Distribution by Type of Cells Manufactured
Figure 14.7 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 14.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Number of Initiatives
Figure 14.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Type of Initiative
Figure 14.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Type of Cells Manufactured
Figure 14.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Figure 14.12 Harvey Ball Analysis: Big Pharma Initiatives Summary
Figure 14.13 Spider Web Analysis: Big Pharmaceutical Players
Figure 15.1 Installed Global Capacity of Industry Players for Cell Therapy Manufacturing (Number of Cleanrooms): Distribution by Company Size and Range of Installed Capacity
Figure 15.2 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 15.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Figure 15.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Figure 15.5 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 15.6 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 15.7 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 15.8 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Company Size
Figure 15.9 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 15.10 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 15.11 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 15.12 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 15.13 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Range of Installed Capacity
Figure 15.14 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Figure 15.15 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 15.16 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Range of Installed Capacity
Figure 15.17 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 15.18 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 16.1 Global Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Figure 16.2 Global Demand for Cell Therapies (Billion Cells), 2022-2035
Figure 16.3 Global Clinical Demand for Cell Therapies (Number of Patients), 2022-2035
Figure 16.4 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Figure 16.5 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Figure 16.6 Global Commercial Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Figure 16.7 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Figure 16.8 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Figure 17.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 18.1 Make versus Buy Decision Making Framework
Figure 18.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 19.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 19.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 19.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 19.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 19.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 19.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 20.1 Global Cell Therapy Manufacturing Market, 2022-2035 (USD Million)
Figure 20.2 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022-2035 (USD Million)
Figure 20.3 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.4 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 20.5 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million) 
Figure 20.6 Cell Therapy Manufacturing Market: Distribution by Region, 2022-2035 (USD Million)
Figure 20.7 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035 (USD Million)
Figure 20.8 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 20.9 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.10 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.11 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Figure 20.12 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Figure 20.13 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Figure 20.14 Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 20.15 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Figure 20.16 Global Commercial Scale Manufacturing Market for Stem Cell Therapies,2022-2035 (USD Million)
Figure 20.17 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Figure 20.18 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Figure 20.19 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035(USD Million)
Figure 20.20 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Typeof Therapy, 2022-2035 (USD Million)
Figure 20.21 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.22 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.23 Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 20.24 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.25 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Figure 20.26 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035(USD Million)
Figure 20.27 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.28 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.29 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Figure 20.30 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.31 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 21.1 Cell Therapy Manufacturing: Grid Analysis by Type of Cells Manufactured, Scale of Operation and Purpose of Manufacturing
Figure 21.2 Immune Cell Therapy Manufacturing: Logo Landscape
Figure 21.3 Stem Cell Therapy Manufacturing: Logo Landscape
Figure 21.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters
Figure 21.5 Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
Figure 22.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Partnerships and Collaborations
Figure 23.3 Concluding Remarks: Mergers and Acquisitions
Figure 23.4 Concluding Remarks: Recent Expansions
Figure 23.5 Concluding Remarks: Big Pharma Initiatives
Figure 23.6 Concluding Remarks: Capacity Analysis
Figure 23.7 Concluding Remarks: Demand Analysis
Figure 23.8 Concluding Remarks: Total Cost of Ownership
Figure 23.9 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 23.10 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2))
Figure 24.1 Survey Analysis: Distribution of Respondents by Type of Organization
Figure 24.2 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Figure 24.3 Survey Analysis: Distribution by Designation of Respondents
Figure 24.4 Survey Analysis: Distribution by Type of Cell Therapy
Figure 24.5 Survey Analysis: Distribution by Scale of Operation
Figure 24.6 Survey Analysis: Distribution by Source of Cells
Figure 24.7 Survey Analysis: Distribution by Type of Cell Culture System
Figure 24.8 Survey Analysis: Distribution by Availability of Fill / Finish Services

List Of Tables

Table 3.1 Cell-based Therapies: Key Applications
Table 3.2 Differences between Cell-based Therapies and Other Biotechnological Products
Table 3.3 Cell-based Therapies: Commercialized Products
Table 3.4 Assessments for Key Cell Therapy Manufacturing Steps
Table 3.5 Advantages and Disadvantages Associated with Centralized and Decentralized Manufacturing Models
Table 4.1 Cell Therapy Manufacturing: List of Industry Players
Table 4.2 Cell Therapy Manufacturing (Industry Players): Information on Type of Manufacturer
Table 4.3 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 4.4 Cell Therapy Manufacturing (Industry Players): Information on Source of Cells and Type of Cells Culture System Used
Table 4.5 Cell Therapy Manufacturing (Industry Players): Information on Scale of Operation
Table 4.6 Cell Therapy Manufacturing (Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 4.7 Cell Therapy Manufacturing: List of Non-Industry Players
Table 4.8 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Manufacturer
Table 4.9 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Cell Manufactured
Table 4.10 Cell Therapy Manufacturing (Non-Industry Players): Information on Source of Cells and Type of Cells Culture System Used
Table 4.11 Cell Therapy Manufacturing (Non-Industry Players): Information on Scale of Operation
Table 4.12 Cell Therapy Manufacturing (Non-Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 5.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities /Certifications
Table 5.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities /Certifications
Table 5.3 Cell Therapy: Regulatory Considerations
Table 6.1 Cell Therapy Manufacturing: Roadmap for the US
Table 6.2 Cell Processing: Challenges and Strategies
Table 6.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 6.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 6.5 Standardization and Regulatory Support: Challenges and Strategies
Table 6.6 Workforce Development: Challenges and Strategies
Table 6.7 Supply Chain and Logistics: Challenges and Strategies
Table 6.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific EconomicCooperation (APEC)
Table 7.1 Cell Therapy Manufacturing: List of Automated and Closed Cell TherapyProcessing Systems
Table 7.2 Cell Therapy Manufacturing: Observed Changes in Scale-up Scenario while Switching from Manual to Automated Operations
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Overview of Manufacturing Facilities and Capabilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Charles River Laboratories: Company Overview
Table 8.5 Charles River Laboratories: Overview of Manufacturing Facilities and Capabilities
Table 8.6 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.7 KBI Biopharma: Company Overview
Table 8.8 KBI Biopharma: Overview of Manufacturing Facilities and Capabilities
Table 8.9 KBI Biopharma: Recent Developments and Future Outlook
Table 8.10 Thermo Fisher Scientific: Company Overview
Table 8.11 Thermo Fisher Scientific: Overview of Manufacturing Facilities and Capabilities
Table 8.12 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.13 BioNTech Innovative Manufacturing Services: Company Overview
Table 8.14 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Facilities and Capabilities
Table 8.15 BioNTech Innovative Manufacturing Services: Recent Developments and Future Outlook
Table 8.16 Cell and Gene Therapy Catapult: Company Overview
Table 8.17 Cell and Gene Therapy Catapult: Overview of Manufacturing Facilities and Capabilities
Table 8.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 8.19 Lonza: Company Overview
Table 8.20 Lonza: Overview of Manufacturing Facilities and Capabilities
Table 8.21 Lonza: Recent Developments and Future Outlook
Table 8.22 RoslinCT: Company Overview
Table 8.23 RoslinCT: Overview of Manufacturing Facilities and Capabilities
Table 8.24 RoslinCT: Recent Developments and Future Outlook
Table 8.25 Cell Therapies: Company Overview
Table 8.26 Cell Therapies: Overview of Manufacturing Facilities and Capabilities
Table 8.27 Cell Therapies: Recent Developments and Future Outlook
Table 8.28 FUJIFILM Cellular Dynamics: Company Overview
Table 8.29 FUJIFILM Cellular Dynamics: Overview of Manufacturing Facilities and Capabilities
Table 8.30 FUJIFILM Cellular Dynamics: Recent Developments and Future Outlook
Table 8.31 Minaris Regenerative Medicine: Company Overview
Table 8.32 Minaris Regenerative Medicine: Overview of Manufacturing Facilities and Capabilities
Table 8.33 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 8.34 MEDINET: Company Overview
Table 8.35 MEDINET: Overview of Manufacturing Facilities and Capabilities
Table 8.36 Nikon CeLL Innovation: Company Overview
Table 8.37 Nikon CeLL Innovation: Overview of Manufacturing Facilities and Capabilities
Table 8.38 WuXi AppTec: Company Overview
Table 8.39 WuXi AppTec: Overview of Manufacturing Facilities and Capabilities
Table 8.40 WuXi AppTec: Recent Developments and Future Outlook
Table 9.1 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 9.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
Table 9.3 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.4 Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.5 Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 9.6 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 9.7 Newcastle Cellular Therapies Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.8 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 9.9 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine: Overview of Manufacturing Services and Capabilities
Table 9.10 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 10.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 10.2 CellCAN: Overview
Table 10.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 10.4 National Cell Manufacturing Consortium: Overview
Table 10.5 California’s Institute of Regenerative Medicine: Overview
Table 12.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
Table 12.2 Partnerships and Collaborations: Information on Type of Cells
Table 12.3 Partnerships and Collaborations: Information on Type of T Cells and Stem Cells
Table 12.4 Partnerships and Collaborations: Information on Scale of Operation
Table 12.5 Cell Therapy Manufacturing: List of Mergers and Acquisitions
Table 13.1 Cell Therapy Manufacturing: List of Expansions
Table 13.2 Recent Expansions: Information on Type of Cells Manufactured
Table 13.3 Recent Expansions: Information on Scale of Operation
Table 14.1 Big Pharma Initiatives: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
Table 14.2 Big Pharma Initiatives: Information on Type of Cells Manufactured
Table 14.3 Big Pharma Initiatives: Information on Scale of Operation
Table 15.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
Table 15.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
Table 15.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Table 15.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size
Table 15.5 Installed Global Capacity for Cell Therapy Manufacturing (in Terms of Number of Cleanrooms): Average Capacity for Non-Industry Players
Table 15.6 Installed Global Capacity for Cell Therapy Manufacturing (in Terms of Cleanroom Area, Sq. ft.): Average Capacity for Non-Industry Players
Table 17.1 Costs Associated with the Manufacturing of Stem Cell Therapies
Table 17.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
Table 17.3 T-cell Immunotherapies: Expert Opinions on Pricing
Table 17.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 19.1 Total Cost of Ownership: Sample Dataset
Table 20.1 Active Clinical Studies for Autologous Cell Therapies
Table 20.2 Active Clinical Studies for Autologous Cell Therapies: Distribution by Patients Enrolled
Table 20.3 Active Clinical Studies for Allogeneic Cell Therapies
Table 20.4 Active Clinical Studies for Allogeneic Cell Therapies: Distribution by Patients Enrolled
Table 24.1 Survey Analysis: Overview of Respondents
Table 24.2 Survey Analysis: Designations and Seniority Levels
Table 24.3 Survey Analysis: Type of Cell Therapy
Table 24.4 Survey Analysis: Scale of Operation
Table 24.5 Survey Analysis: Source of Cells
Table 24.6 Survey Analysis: Cell Culture System Used
Table 24.7 Survey Analysis: Availability of Fill / Finish Services
Table 25.1 RoslinCT: Key Highlights
Table 25.2 Discovery Life Sciences: Key Highlights
Table 25.3 Glycostem Therapeutics: Key Highlights
Table 25.4 Bio Elpida: Key Highlights
Table 25.5 Gracell Biotechnologies: Key Highlights
Table 25.6 Kadimastem: Key Highlights
Table 25.7 RoslinCT: Key Highlights
Table 25.8 University of Minnesota: Key Highlights
Table 25.8 Lion TCR: Key Highlights
Table 25.10 Center for Commercialization of Cancer Immunotherapy (C3i): Key Highlights
Table 25.11 Yposkesi: Key Highlights
Table 25.12 CiMaas: Key Highlights
Table 26.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Table 26.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Table 26.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 26.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 26.5 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Location of Headquarters
Table 26.6 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment and Location of Headquarters
Table 26.7 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Table 26.8 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Table 26.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Table 26.10 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Table 26.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cells Manufactured
Table 26.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 26.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 26.14 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Type of Cells Manufactured
Table 26.15 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Cells Manufactured
Table 26.16 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Table 26.17 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cells Manufactured and Source of Cells
Table 26.18 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Table 26.19 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 26.20 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Services Offered
Table 26.21 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Table 26.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size
Table 26.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment
Table 26.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 26.25 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 26.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Table 26.27 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment and Location of Headquarters
Table 26.28 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.29 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.30 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Table 26.31 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Table 26.32 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cells Manufactured
Table 26.33 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Table 26.34 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Table 26.35 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Type of Cells Manufactured
Table 26.36 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Cells Manufactured
Table 26.37 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Table 26.38 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cells Manufactured and Source of Cells
Table 26.39 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Table 26.40 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 26.41 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Services Offered
Table 26.42 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Table 26.43 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2022
Table 26.44 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2022
Table 26.45 Clinical Trial Analysis: Distribution by Trial Status
Table 26.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.48 Clinical Trial Analysis: Distribution of Number of Trials by Enrolled Patient Population and Trial Phase
Table 26.49 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.50 Clinical Trial Analysis: Distribution by Patient Segment
Table 26.51 Clinical Trial Analysis: Distribution by Study Design
Table 26.52 Most Active Industry Players: Distribution by Number of Registered Trials
Table 26.53 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 26.54 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Table 26.55 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Table 26.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 26.57 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.58 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.59 Partnerships and Collaborations: Distribution by Type of Cells
Table 26.60 Heat Map: Distribution by Year and Type of Cells
Table 26.61 Partnerships and Collaborations: Distribution by Type of T-Cell
Table 26.62 Partnerships and Collaborations: Distribution by Type of Stem Cell
Table 26.63 Partnerships and Collaborations: Distribution by Scale of Operation
Table 26.64 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Table 26.65 Partnerships and Collaborations: Country-wise Distribution
Table 26.66 Partnerships and Collaborations: Continent-wise Distribution
Table 26.67 Most Active Players: Distribution by Number of Partnerships
Table 26.68 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022 (till June)
Table 26.69 Mergers and Acquisitions: Distribution by Type of Agreement
Table 26.70 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Table 26.71 Mergers and Acquisitions: Country-wise Distribution
Table 26.72 Mergers and Acquisitions: Continent-wise Distribution
Table 26.73 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 26.74 Mergers and Acquisitions: Ownership Change Matrix
Table 26.75 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 26.76 Recent Expansions: Distribution by Type of Expansion
Table 26.77 Recent Expansions: Distribution by Year and Type of Expansion
Table 26.78 Recent Expansions: Distribution by Type of Cells Manufactured
Table 26.79 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Table 26.80 Recent Expansions: Distribution by Scale of Operation
Table 26.81 Recent Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.82 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.83 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Table 26.84 Most Active Players: Distribution by Area of Expansion (in sq ft)
Table 26.85 Big Pharma Initiatives: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Table 26.86 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2017-2022
Table 26.87 Big Pharma Initiatives: Distribution by Type of Initiative
Table 26.88 Big Pharma Initiatives: Distribution by Type of Partnership
Table 26.89 Big Pharma Initiatives: Distribution by Type of Expansion
Table 26.90 Big Pharma Initiatives: Distribution by Type of Cells Manufactured
Table 26.91 Big Pharma Initiatives: Distribution by Scale of Operation
Table 26.92 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Number of Initiatives
Table 26.93 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Type of Initiative
Table 26.94 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Table 26.95 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Table 26.96 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 26.97 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Table 26.98 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 26.99 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size
Table 26.100 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation
Table 26.101 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Location of Manufacturing Facility
Table 26.102 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size and Location of Manufacturing Facility
Table 26.103 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 26.104 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Table 26.105 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 26.106 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation
Table 26.107 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Location of Manufacturing Facility
Table 26.108 Global Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Table 26.109 Global Demand for Cell Therapies (Billion Cells), 2022-2035
Table 26.110 Global Clinical Demand for Cell Therapies, 2022-2035 (Number of Patients)
Table 26.111 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Table 26.112 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Table 26.113 Global Commercial Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Table 26.114 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Table 26.115 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Table 26.116 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Table 26.117 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 26.118 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 26.119 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations,Y1-Y20: Distribution by OPEX(USD Million)
Table 26.120 Global Cell Therapy Manufacturing Market, 2022-2035 (USD Million)
Table 26.121 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy,2022-2035 (USD Million)
Table 26.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 26.123 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 26.124 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing,2022-2035 (USD Million) 
Table 26.125 Cell Therapy Manufacturing Market: Distribution by Region, 2022-2035 (USDMillion)
Table 26.126 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035 (USD Million)
Table 26.127 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byType of Therapy, 2022-2035 (USD Million)
Table 26.128 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.129 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.130 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Table 26.131 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Table 26.132 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Table 26.133 Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 26.134 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Table 26.135 Global Commercial Scale Manufacturing Market for Stem Cell Therapies,2022-2035 (USD Million)
Table 26.136 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Table 26.137 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Table 26.138 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035(USD Million)
Table 26.139 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Typeof Therapy, 2022-2035 (USD Million)
Table 26.140 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.141 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.142 Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 26.143 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 26.144 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Table 26.145 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035(USD Million)
Table 26.146 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.148 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.149 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 26.150 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.151 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.152 Survey Analysis: Distribution of Respondents by Type of Organization
Table 26.153 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Table 26.154 Survey Analysis: Distribution by Designation of Respondents
Table 26.155 Survey Analysis: Distribution by Type of Cell Therapies
Table 26.156 Survey Analysis: Distribution by Scale of Operation
Table 26.157 Survey Analysis: Distribution by Source of Cells
Table 26.158 Survey Analysis: Distribution by Availability of Fill / Finish Services                                                                                                                                Table 26.159 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.160 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.161 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 26.162 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.163 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.164 Cell Therapy Manufacturing: Grid Analysis by Type of Cells Manufactured, Scale of Operation and Purpose of Manufacturing
Table 26.165 Survey Analysis: Distribution of Respondents by Type of Organization
Table 26.166 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Table 26.167 Survey Analysis: Distribution by Designation of Respondents
Table 26.168 Survey Analysis: Distribution by Type of Cell Therapies
Table 26.169 Survey Analysis: Distribution by Scale of Operation
Table 26.170 Survey Analysis: Distribution by Source of Cells
Table 26.171 Survey Analysis: Distribution by Type of Cells Culture System
Table 26.172 Survey Analysis: Distribution by Availability of Fill / Finish Services

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 3SBio
  2. 3P Biopharmaceuticals
  3. A*STAR’s Bioprocessing Technology Institute (BTI)
  4. A2 Biotherapeutics
  5. A2 Healthcare
  6. Abeona Therapeutics
  7. Accellta
  8. Achilles Therapeutics
  9. Adaptate Biotherapeutics
  10. Adaptimmune Therapeutics
  11. Adva Biotechnology
  12. Advance BioScience Laboratories (ABL)
  13. Advanced Cell Therapy Laboratory (ACTL)
  14. Advanced Regenerative Manufacturing Institute
  15. Advent Bioservices
  16. AGC Biologics
  17. Agilent Technologies
  18. Aglaris
  19. Akron Biotech
  20. Alberta Cell Therapy Manufacturing (ACTM)
  21. Allele Biotechnology and Pharmaceuticals
  22. Allogene Therapeutics
  23. Anemocyte
  24. anicells
  25. Anterogen
  26. Antion Biosciences
  27. apceth Biopharma
  28. Appia Bio
  29. ArchiMed
  30. Argos Therapeutics
  31. Arsenal Biosciences
  32. Artiva Biotherapeutics
  33. Asahi Glass
  34. Ascend Gene and Cell Therapies
  35. Aseptic Technologies
  36. Aspire Health Science
  37. Astellas Pharma
  38. Asterias Biotherapeutics
  39. Astero Bio
  40. ASTRAVEUS
  41. Asymptote
  42. Atara Biotherapeutics
  43. Athersys
  44. Austrianova
  45. Autolus
  46. Avalon GloboCare
  47. Avectas
  48. Avery Therapeutics
  49. Bayer
  50. Be Biopharma
  51. Be The Match BioTherapies
  52. Bellicum Pharmaceuticals
  53. Bio Elpida
  54. BioCardia
  55. BioCentriq
  56. Bioinova
  57. BioNTech
  58. BioRestorative Therapies
  59. BioTherapeutics Unit, Netherlands Cancer Institute
  60. bluebird bio
  61. BlueRock Therapeutics
  62. Bone Therapeutics
  63. Boston Children's Hospital
  64. Boyalife
  65. BrainStorm Cell Therapeutics
  66. Brammer Bio
  67. BriaCell Therapeutics
  68. Bristol Myers Squibb
  69. Centre for Commercialization of Cancer Immunotherapy (C3i)
  70. Caladrius Biosciences
  71. CANCER RESEARCH TECHNOLOGY (CRT)
  72. CancerRop
  73. Capricor Therapeutics
  74. CariCord
  75. Carisma Therapeutics
  76. CARsgen Therapeutics
  77. Cartesian Therapeutics
  78. Cartexell
  79. CaseBioscience
  80. Catalent
  81. Catapult Therapy TCR (Acquired by Cell Medica)
  82. Cbio
  83. Cedars-Sinai Biomanufacturing Center
  84. Celgene
  85. Cell and Gene Therapy Catapult
  86. Cell and Gene Therapy Laboratory, Children’s Hospital of Philadelphia
  87. Cell Medica
  88. Cell Therapies
  89. Cell Therapies Core, Moffitt Cancer Center
  90. Cell Therapy and Regenerative Medicine, University of Utah
  91. Regenerative Medicine Center, Utrecht University
  92. Cell Therapy Manufacturing Facility, MedStar Georgetown University Hospital
  93. Cell Therapy Suite, University of Birmingham
  94. Cellaïon
  95. Cellares
  96. Cellatoz Therapeutics
  97. Cell-Easy
  98. Cellectis
  99. Cellevolve Bio
  100. Cellex Cell Professionals
  101. CELLforCURE
  102. Cellin Technologies
  103. Cellino
  104. Cellipont Bioservices
  105. Cellistic
  106. Cell Manufacturing and Production
  107. CellPoint
  108. Cells for Sight Stem Cell Therapy Research Unit, University College London
  109. Cellular Biomedicine Group
  110. Cellular Therapy Core, Sidney Kimmel Comprehensive Cancer Center
  111. Cellular Therapy Core, University of Texas
  112. Cellular Therapy Integrated Services, Case Western Reserve University
  113. Celonic
  114. Celularity
  115. Celyad Oncology
  116. Center for Biomedical Engineering and Advanced Manufacturing, McMaster
  117. Center for Breakthrough Medicines
  118. Center for Cellular Immunotherapies
  119. Center for Cell and Gene Therapy, Baylor College of Medicine
  120. Center for International Blood and Marrow Transplant Research
  121. Centre for Biological Engineering, Loughborough University
  122. Centre for Cell and Vector Production
  123. Centre for Cell Manufacturing Ireland, NUI Galway
  124. Centre for Stem Cell Research (CSCR), Christian Medical College
  125. Century Therapeutics
  126. Cesca Therapeutics
  127. cGMPnow
  128. CHA Biolab
  129. CHA Biotech
  130. Charles River Laboratories
  131. Chart Industries
  132. Chiesi Farmaceutici
  133. Children's GMP, St. Jude Children's Research Hospital
  134. Children's National Hospital
  135. Chimeric Therapeutics
  136. China Life Health Industry Group
  137. China Regenerative Medicine International
  138. IQVIA Cell And Gene Therapy Center
  139. City of Hope
  140. Clean Cells
  141. Clinical Biomanufacturing Facility, University of Oxford
  142. Clinical Cell and Vaccine Production Facility
  143. CMIC Group
  144. CO.DON
  145. Cogent Biosciences
  146. Cognate BioServices
  147. CoImmune
  148. CCRM
  149. Comprehensive Cell Solutions™
  150. Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF)
  151. Cook MyoSite
  152. CPI
  153. Creative Biolabs
  154. Crescendo Biologics
  155. CRISPR Therapeutics
  156. Cryoport
  157. CSIRO
  158. CTM CRC
  159. CUORiPS
  160. Cynata Therapeutics
  161. Cytiva
  162. Cytonet
  163. Cytosen Therapeutics
  164. Cytovance Biologics
  165. Daiichi Sankyo
  166. Dendreon Pharmaceuticals
  167. David and Etta Jonas Center for Cellular Therapy, UChicago Medicine
  168. DCPrime
  169. Deep Science Ventures
  170. Delphi Genetics
  171. Dendreon
  172. Draper
  173. Duke-NUS Medical School
  174. ElevateBio
  175. Emory Cellular and Immunotherapy Core (ExCITE)"
  176. Empirica Therapeutics (Acquired by Century Therapeutics)
  177. ENABLE SPARKS Cells
  178. ERYTECH Pharma
  179. Esco Aster
  180. Esco VacciXcell
  181. EUFETS
  182. Eutilex
  183. Exacis Biotherapeutics
  184. Excellos
  185. ExCellThera
  186. eXmoor Pharma
  187. Expression Therapeutics
  188. FamiCord
  189. Fate Therapeutics
  190. Flaskworks (Acquired by Northwest Biotherapeutics)
  191. FloDesign Sonics
  192. Forecyte Bio
  193. Formula Pharmaceuticals
  194. Fosun Pharma
  195. Fraunhofer Institute for Cell Therapy and Immunology
  196. Fred Hutchinson Cancer Research Center
  197. French Blood Agency
  198. Fresenius Kabi
  199. Froceth
  200. FUJIFILM Cellular Dynamics
  201. FUJIFILM Diosynth Biotechnologies
  202. FutureGen Biopharm
  203. Gamida Cell
  204. GammaDelta Therapeutics
  205. Gates Biomanufacturing Facility
  206. GC Cell
  207. GE Healthcare Life Sciences
  208. GenCure
  209. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  210. Genentech
  211. Genexine
  212. Genezen
  213. GenIbet Biopharmaceuticals
  214. German Red Cross Blood Donor Service
  215. Ghent University
  216. GI Cell
  217. Gilead Sciences
  218. GlaxoSmithKline
  219. Glycostem Therapeutics
  220. Glycotope
  221. GPB Scientific
  222. Gracell Biotechnologies
  223. Great Ormond Street Hospital Cellular Therapy Laboratories, University College of London
  224. GX Acquisition
  225. H. Lee Moffitt Cancer Center and Research Institute
  226. Haemonetics
  227. Harvard University Stem Cell Institute
  228. Health Sciences Authority (HSA)
  229. Hebei Senlang Biotechnology
  230. Helixmith
  231. Hemostemix
  232. Histocell
  233. Hitachi Chemical
  234. Holostem Terapie Avanzate
  235. Human Islet and Cellular Transplant Facility
  236. August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
  237. I Peace
  238. IASO Biotherapeutics
  239. Immatics
  240. Immuneel Therapeutics
  241. ImmunityBio
  242. Immunomic Therapeutics
  243. Immunovative Therapies
  244. Immusoft
  245. Imugene
  246. IncoCell Tianjin
  247. Indapta Therapeutics
  248. Innovative Cellular Therapeutics
  249. Instil Bio
  250. Intellia Therapeutics
  251. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  252. International Stem Cell Corporation
  253. Invetech
  254. Iovance Biotherapeutics
  255. IsoPlexis
  256. Ixaka
  257. Janssen Biotech
  258. Janssen Pharmaceuticals
  259. Japan Tissue Engineering
  260. Jiuzhitang Maker Cell Technology
  261. John Goldman Centre for Cellular Therapy, Imperial College London
  262. Juno Therapeutics
  263. JW CreaGene
  264. JW Therapeutics
  265. Kadimastem
  266. Kangstem Biotech
  267. Karolinska Institutet
  268. Kawasaki Heavy Industries
  269. KBI Biopharma
  270. Kemwell Biopharma
  271. Kiadis Pharma
  272. King's Clinical Research Facility
  273. Kite Pharma
  274. KOLON Biotech
  275. Krembil Cell Facility, St. Michael’s Hospital
  276. KSQ Therapeutics
  277. Laboratory for Cell and Gene Medicine, University of Stanford
  278. Legend Biotech
  279. Limula
  280. Lineage Cell Therapeutics
  281. Lion TCR
  282. Longeveron
  283. Lonza
  284. Lorem Cytori
  285. LumaCyte
  286. Lyell Immunopharma
  287. Lykan Bioscience
  288. Lymphotec
  289. Marker Therapeutics
  290. Massachusetts General Hospital
  291. MaSTherCell
  292. Matica Biotechnology
  293. MaxiVAX
  294. Human Cellular Therapy Laboratory, Mayo Clinic
  295. MD Anderson Cancer Center
  296. Medace
  297. Medeor Therapeutics
  298. Medera
  299. Medigene
  300. MEDINET
  301. MEDIPOST
  302. MedTherapy
  303. Membio
  304. Memorial Sloan Kettering Cancer Center
  305. Merck
  306. Mesoblast
  307. MicrofluidX
  308. Midwest Stem Cell Therapy Center, University of Kansas Medical Center
  309. Miltenyi Biotec
  310. Minaris Regenerative Medicine
  311. MiNK Therapeutics
  312. Minovia Therapeutics
  313. Molecular and Cellular Therapeutics, University of Minnesota
  314. MolMed
  315. Mustang Bio
  316. Nagoya University
  317. Nanjing Cenbest
  318. KAEDI
  319. NantKwest
  320. National Cancer Institute
  321. National Eye Institute
  322. National Resilience
  323. Ncardia
  324. Neon Therapeutics
  325. NeoProgen
  326. New Jersey Innovation Institute (NJII)
  327. Newcastle Advanced Therapies
  328. NextCell Pharma
  329. NHS Blood and Transplant
  330. NIHR Clinical Research Facility (CRF) at Guy’s and St Thomas’
  331. Nikon CeLL innovation
  332. Nippon Shinyaku
  333. Nipro
  334. NiSCELL
  335. Nkarta
  336. NKGen Biotech (Formerly known as NKMax America)
  337. Nohla Therapeutics
  338. Noile-Immune Biotech
  339. Northwest Biotherapeutics
  340. Notch Therapeutics
  341. Novadip Biosciences
  342. Novartis
  343. Novartis Gene Therapies
  344. Novex Innovations
  345. Novo Nordisk
  346. ObiO Technology
  347. Octane Biotech
  348. ONK Therapeutics
  349. Ono Pharmaceutical
  350. Ontario Institute for Regenerative Medicine
  351. Opexa Therapeutics
  352. Orca Bio
  353. OrganaBio
  354. Orgenesis
  355. Ori Biotech
  356. Ospedale Pediatrico Bambino Gesù
  357. OSPIN
  358. Overland Pharmaceuticals
  359. Ovizio Imaging Systems
  360. Oxford MEStar
  361. OXGENE
  362. Pall Corporation
  363. PanCryos
  364. Parker Institute for Cancer Immunotherapy
  365. PCT
  366. Performance Cell Manufacturing
  367. PersonGen BioTherapeutics
  368. PharmaBio
  369. PharmaCell
  370. Pharmicell
  371. pHion Therapeutics
  372. Pierre Fabre
  373. Pluristem Therapeutics
  374. Precision BioSciences
  375. Promethera Biosciences
  376. Provia Laboratories
  377. Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
  378. QIMR Berghofer Medical Research Institute
  379. QuaCell Biotechnology
  380. Quell Therapeutics
  381. Rayne Cell Therapy Suite
  382. Recipharm
  383. Regeneus
  384. ReNeuron
  385. Rentschler ATMP
  386. Rentschler Biopharma
  387. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  388. Rexgenero
  389. RheinCell Therapeutics (Acquired by Catalent)
  390. Rivaara Immune
  391. Riyadh Pharma
  392. Robertson Clinical and Translational Cell Therapy, Duke University
  393. RoosterBio
  394. RoslinCT
  395. Centre for Cell and Gene Tissue Therapeutics, Royal Free Hospital London
  396. Rubius Therapeutics
  397. Rutgers Cancer Institute of New Jersey
  398. S.Biomedics
  399. Saint-Gobain
  400. SAKARTA
  401. Sana Biotechnology
  402. SanBio
  403. Sangamo Therapeutics
  404. Sanpower
  405. Sartorius
  406. SCG Cell Therapy
  407. Scinogy
  408. Scinus Cell Expansion
  409. SCM Lifescience
  410. Scottish National Blood Transfusion Service
  411. SCTbio
  412. Secarna Pharmaceuticals
  413. Senti Biosciences
  414. Servier
  415. Shanghai Ucardi Biomedical Technology
  416. Sheba Medical Center
  417. Shibuya
  418. Shinshu University
  419. Shoreline Biosciences
  420. SingCell
  421. Skeletal Cell Therapy Support (Acquired by Catalent)
  422. Sorrento Therapeutics
  423. SOTIO
  424. Southwest Research Institute
  425. S-RACMO
  426. Stanford University School of Medicine
  427. Stem Cell Institute
  428. STEMCELL Technologies
  429. Stemedica Cell Technologies
  430. Stemmatters
  431. Stempeutics Research
  432. Sumitomo Dainippon Pharma
  433. Suzhou Porton Biologics
  434. Sydney Cell and Gene Therapy
  435. Syngen Biotech
  436. Takara Bio
  437. Takeda
  438. TapImmune
  439. TC BioPharm
  440. TCR2 Therapeutics
  441. TCRCure Biopharma
  442. Terumo Blood and Cell Technologies
  443. Tessa Therapeutics
  444. Tevogen Bio
  445. The Discovery Labs Center for Breakthrough Medicines
  446. The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  447. The Netherlands Cancer Institute
  448. The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen)
  449. The Ottawa Hospital Research Institute
  450. The Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital
  451. The University of Texas MD Anderson Cancer Center
  452. Therabest
  453. Theragent
  454. Therapeutic Cell Production Core, Seattle Children's Hospital
  455. Therapeutic Cell Production Facility, Roswell Park Comprehensive Cancer Center
  456. Thermo Fisher Scientific
  457. ThermoGenesis
  458. TiGenix
  459. Tissue Genesis
  460. T-knife
  461. Tmunity Therapeutics
  462. TrakCel
  463. Treadwell Therapeutics
  464. TreeFrog Therapeutics
  465. Triumvira Immunologics
  466. Trizell
  467. TVAX Biomedical
  468. TxCell
  469. UC Davis GMP Laboratory
  470. UCLA Human Gene and Cell Therapy
  471. Universal Cells
  472. University Hospital Basel
  473. University of Chicago Medicine
  474. University of North Carolina Lineberger Comprehensive Cancer Center
  475. Upstate Stem Cell cGMP Facility (USCGF), University of Rochester
  476. UW Program for Advanced Cell Therapy (PACT)
  477. Vanrx Pharmasystems
  478. Vecura
  479. Vericel
  480. Vineti
  481. Vinta Bio
  482. Viscofan BioEngineering
  483. VivaBioCell
  484. Waisman Biomanufacturing
  485. Wilson Wolf Manufacturing
  486. Wugen
  487. WuXi Advanced Therapies
  488. Xintela
  489. Zelluna Immunotherapy

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com